S90 Diabetes Care Volume 38, Supplement 1, January 2015 Index A1C. see also glycemic targets cardiovascular disease changes, initiatives, S6 CGM, S34 A1C relationship to, S36 demographic changes, S5 children and adolescents, S35, S71 autonomic neuropathy, S25, S62–S63 improvement strategies, S5 glycemic target determination, S37 children and adolescents, S72 patient-centeredness, S5 goals, S35 dietary fat management, S23–S24 regime reevaluation, S6–S7 limitations, S34–S35 patient-centeredness, S5 resources, S6 macrovascular complications, S36 pharmacological therapy, S51–S55, S59 clonidine, S78 mean glucose levels, S35 postprandial plasma glucose testing, S37 clopidogrel, S54, S55 microvascular complications, S35–S36 revisions summary, S4 cognitive impairment, S19, S38, S70 race/ethnicity differences, S9, S35 risk calculator, S52 colesevelam, S42, S44 recommendations, S34, S35, S37 risk factors, S10, S12, S25, S32 comorbidities, S17–S19, S26 SMBG, S33–S34 risk management, S49–S55 congestive heart failure, S51, S55 testing, S8–S10, S12, S34–S35 screening, S31, S55 consensus reports, S1 acarbose, S44 testing frequency, S9 continuous glucose monitoring (CGM), S4, ACCORD trial, S19, S36, S38, S50, S53 Care of Young Children With Diabetes in the S33, S34 A1C Derived Average Glucose (ADAG) trial, Child Care Setting,S86 continuous subcutaneous insulin infusion S35, S37 celiac disease, S71 (CSII), S83 ACE inhibitors, S49–S51, S55, S58–S60, Charcot foot, S64 contraception, S79 S72, S78 children and adolescents coronary heart disease, S55 acute coronary syndrome, S54, S55 A1C goals, S35, S71 cystic fibrosis–related diabetes, S15 adolescents. see children and autoimmune conditions, S71 adolescents cardiovascular disease, S72 dapagliflozin, S45 ADVANCE-BP trial, S50, S51 celiac disease, S71 Da Qing study, S31 ADVANCE trial, S36, S38 cognitive impairment, S70 DAWN2 study, S26 advocacy, S5, S86–S87 DSME/DSMS, S73 day care, S73, S86–S87 African Americans, S9, S11, S12, S24, S35 dyslipidemia, S72 degludec, S45 age. see older adults family stresses, S74 depression, S18, S26, S67, S74 AIM-HIGH trial, S53 glycemic control, S70–S71 detemir, S45 albiglutide, S45 hypertension, S71–S72 Diabetes and Driving, S86 albuminuria, S25, S58–S60, S73 hypoglycemia, S70 Diabetes and Employment, S86 alcohol, S23, S51 nephropathy, S72–S73 Diabetes Care in the School and Day Care alogliptin, S44 neuropathy, S73 Setting, S86–S87 amlodipine, S51 pediatric to adult care transition, Diabetes Control and Complications Trial amputations, S63–S64 S73–S74 (DCCT), S35, S36, S38, S41, S70 amylin mimetics, S45 plasma blood glucose goals, S71 Diabetes Management in Correctional anemia, S9 psychosocial issues, S74 Institutions, S87 angiotensin receptor blockers (ARBs), resources, S86 Diabetes Prevention Program (DPP), S49–S51, S55, S58–S60, S72, S78 retinopathy, S73 S31, S32 ankle-brachial index (ABI), S63, S64 revisions summary, S4 Diabetes Prevention Program Outcomes antihypertensive medications, S51, school, child care, S73 Study (DPPOS), S31, S32 S59, S78 smoking, S72 diabetes-related distress, S26 antiplatelet agents, S54–S55, S61 statins, S72 diabetes self-management education Antithrombotic Trialists’ (ATT) Collaboration, S54 thyroid disease, S71 (DSME) Asian Americans, S9–S12 type 1 diabetes, S10–S11, S70–S74 benefits, S6, S20–S21 aspart, S43, S45 type 2 diabetes, S12–S13, S74 carbohydrate management, S21–S23 aspirin resistance, S55 chlorthalidone, S51 children and adolescents, S73 aspirin therapy, S54–S55, S61 cholesterol. see also dyslipidemia dietary fat management, S23–S24 assisted living. see hospital care children and adolescents, S72 eating patterns, S21–S23 autoimmune disease, S10–S11 control, S51 herbal supplements, S23 Automation to Simulate Pancreatic Insulin monitoring, S53 hospital care, S84 Response (ASPIRE) trial, S34 screening, S10, S52 medical nutrition therapy, S21–S23, S52, autonomic neuropathy, S25, S62–S63 treatment, S52, S55 S72, S83 Chronic Care Model (CCM), S5, S6 micronutrients, S23 bariatric surgery, S46–S47 chronic kidney disease, S23, S25, S58–S60 national standards, S21 benazepril, S51 classification, diagnosis overview, S17, S20–S21 biguanides, S31, S32, S42–S44 overview, S8 prediabetes, S32 bile acid sequestrants, S42, S44, S53 prediabetes, S9–S10, S12–S13 protein management, S22, S23, S59 b-blockers, S51, S55 revisions summary, S4 recommendations, S20, S31 blood pressure control. see hypertension testing, S8–S10 reimbursement, S21 body mass index (BMI), S12 testing frequency, S9 sodium, S23, S24, S51 bromocriptine, S42, S45 claudication, S63 weight loss, S21, S55 INDEX clinical management diabetes self-management support (DSMS). calcium channel blockers, S51, S59 advocacy, S5, S86–S87 see diabetes self-management education canagliflozin, S45 behavior change support, S6 (DSME) cancer, S18 behavior optimization, S6 Diabetic Retinopathy Study (DRS), S61 carbohydrates, S21–S23 care delivery systems, S6 diastolic blood pressure goals, S4 care.diabetesjournals.org Index S91 diet, nutrition, S21–S23 postpartum care, S79 diastolic blood pressure, S50–S51 diltiazem, S78 recommendations, S13 goals, S49, S50 dipeptidyl peptidase 4 (DPP-4) inhibitors, screening, S10 lifestyle modification, S49, S51 S42–S44, S46, S68 two-step strategy, S13–S14 older adults, S67 disordered eating, S74 glargine, S45 overview, S49–S50 diuretics, S49–S51, S58, S59, S78 gliclazide, S44 pharmacological therapy, S49–S51 dopamine-2 agonists, S45 glimepiride, S44 recommendations, S49 driving, S86 glipizide, S44 screening, S10, S49, S50 dulaglutide, S45 glucagon, S38 sodium guidelines, S24, S51 dyslipidemia. see also cholesterol; glucagon-like peptide 1 (GLP-1) agonists, S42, systolic blood pressure, S50, S59 triglycerides S43, S45, S46, S68, S82 treatment, S49, S50 children and adolescents, S72 a-glucosidase inhibitors, S42, S44 Hypertension Optimal Treatment (HOT) trial, S50 control, S51 glulisine, S43, S45 hypertriglyceridemia, S53 lifestyle modification, S52, S55 glyburide/glibenclamide, S44 hypoglycemia monitoring recommendations, S4, S53 glycemic targets. see also A1C A1C goals, S35, S37 recommendations, S51–S52 A1C/microvascular complications CGM, S34 screening, S51 relationships, S35–S36 children and adolescents, S70 treatment, S52–S55 determination, S37 exercise, S25 glycemic control assessment, S33–S35 hospital care, S80–S82 Early Treatment Diabetic Retinopathy Study hospital care, S80–S82 nocturnal, S34 (ETDRS), S61 intercurrent illness, S39 older adults, S68 eating abnormalities, S74 mean glucose levels, S35 overview, S38 eating patterns, S21–S23 mortality findings, S36 pregnancy, S78 e-cigarettes, S4, S25 older adults, S68 prevention, S38, S82 empagliflozin, S45 pregnancy, S77, S78 recommendations, S38 employment, S86 recommendations, S33, S36–S37 treatment, S38 end-stage renal disease (ESRD), S59 revisions summary, S4 hypoglycemia unawareness Epidemiology of Diabetes Interventions and glycemic treatment approaches CGM, S33, S34 Complications (EDIC) study, S35–S36, S38 bariatric surgery, S46–S47 children and adolescents, S70 erectile dysfunction, S63 pharmacological therapy, S41–S46 effects, characterization, S38 exenatide/exenatide ER, S45, S82 revisions summary, S4 recommendations, S38 exercise gram-positive cocci, S64 albuminuria, S25 immune-mediated diabetes, S10–S11 autonomic neuropathy, S25, S62–S63 hearing impairment, S19 immunization recommendations, S4, benefits, S24 hemoglobinopathies, S9 S26–S27 children, S24 hepatitis B vaccination, S26 impaired fasting glucose (IFG), S10, S31 frequency, type, S24 herbal supplements, S23 impaired glucose tolerance (IGT), S10, S31 glycemic control, S24 hospital care incretin-based therapies, S42 hyperglycemia, S25 bedside blood glucose monitoring, S83 indapamide, S50, S51 hypoglycemia, S25 critically ill patients, S80, S81 infections, S64 kidney disease, S23, S25, S58–S60, discharge planning, S80, S83 influenza vaccine, S26–S27 S72–S73 DSME, S84 insulin peripheral neuropathy, S25, S62–S63 glucose abnormalities definitions, S81 basal–bolus, S43, S45, S46, S70, prediabetes, S24 glycemic targets, S80–S82 S71, S82 pre-exercise evaluation, S24–S25 hyperglycemia, S80–S81 combination therapy, S42 recommendations, S24 hypoglycemia, S80–S82 glycemic targets, S38 retinopathy, S25, S60–S62, S73 insulin therapy, S80–S82 hospital care, S80–S82 ezetimibe, S53 management team, S82 hypoglycemia treatment, S38 medical nutrition therapy, S83 intensive insulin regimens, S34 fasting plasma glucose testing, S9 medication reconciliation, S83 MDI, S41 fatty liver disease, S18 non critically ill patients, S80–S82 older adults, S68 fenofibrate, S53 recommendations, S80 pregnancy, S78 fibrates, S53 self-management, S82–S83 recommendations, S33 Finnish Diabetes Prevention Study (DPS), S31 sliding scale insulin (SSI), S80, S82 sliding scale insulin (SSI), S80, S82 foot care, S4, S63–S64 structured discharge communication, S83 type 1 diabetes, S41 foot infections, S64 type 1 diabetes, S82 type 2 diabetes, S42–S46 foundations of care revisions summary, S4 hydrochlorothiazide, S51 insulin dependent diabetes, S10–S11 fractures, S18–S19 hyperglycemia insulin pump therapy, S33, S41, S43, S83 FRAX score, S18 cognitive impairment, S19 insulin resistance, S10, S78 fundus photographs, S61 exercise, S25 insulin secretagogues, S38, S68 glycemic target determination, S37 International Association of the Diabetes gastrointestinal neuropathies, S62 hospital care, S80–S81 and Pregnancy Study Groups gastroparesis, S63 older adults, S67, S68 (IADPSG), S13 genitourinary